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Although fine-needle aspiration cytology is considered to be the reference method for evaluating thyroid nodules,
the results are inaccurate in approximately 10-30% of cases. Several studies have attempted to predict the risk of
malignancy in thyroid nodules based on age, nodularity, thyrotropin values, thyroid autoimmune disease, hot/cold
nodule status, and ultrasound parameters. However, no consensus has been found, and none of these parameters
has significantly affected patient management. The management of indeterminate thyroid nodules and re-biopsies
of nodules with initially benign cytological results remain important and controversial topics of discussion. The
Bethesda cytological system and several studies on the use of molecular markers to predict malignancy from
cytological samples of thyroid nodules need further clarification. More in-depth discussions among and continuous
education of the specialists involved in treating thyroid disease are necessary to improve the management of these
patients. This review aims to examine the clinical, laboratory, ultrasound, and scintigraphic parameters that can be
used for thyroid nodule management.
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THYROID NODULES
Thyroid nodules are one of the most common endocrine
diseases in the world. They affect approximately 4 to 7% of
the population in iodine-sufficient areas, with a markedly
increased incidence in iodine-deficient regions (1). Thyroid
nodules are classified as adenomas, carcinomas, or hyper-
plastic lesions based on their macroscopic and microscopic
histological features (1,2).
Adenomas consist of encapsulated lesions derived from
the follicular epithelium, and they may be present in
isolated, macrofollicular (colloid), microfollicular (fetal),
and trabecular/solid (embryonic) forms (2,3). Adenomas
may be functioning (autonomous), in which case they are
proportionally larger than the rest of the parenchyma and
produce excessive thyroid hormones, or non-functioning, in
which case hormone levels are unchanged. Autonomous
adenomas can occur at any age, but they are rarely toxic in
individuals under 60 years of age (4). These nodules are
generally considered benign, with rare cases of malignancy
(5).
Nodular hyperplasic lesions are characteristically present
in multinodular goiter (MNG) and are caused by follicular
cell hyperplasia. In some cases, hyperplasic nodules can
grow and become autonomous even in the absence of
external stimuli (6).
Differentiated thyroid carcinomas (DTCs), which encom-
pass papillary and follicular carcinomas, are relatively
uncommon tumors. They are generally associated with a
good prognosis, with an estimated incidence of 1 to 10 cases/
100,000 people per year. They are the most common
endocrine neoplasm in the world, but they represent only
1% of all malignancies (1,7,9). Undifferentiated or anapla-
stic carcinomas represent approximately 5% of all thyroid
carcinomas, and medullary thyroid carcinoma (MTC), which
is derived from parafollicular cells, may occur sporadically or
familially (1,3,5,8).
Due to the increased use of ultrasonography (US) and the
increased access to cytology analysis through fine-needle
aspiration biopsy (FNAB) guided by US (FNAB-US), the
number of small-sized thyroid gland carcinoma diagnoses
has increased in Brazil and in many other countries (5-8).
Thus, carcinomas smaller than 1 cm in diameter are being
detected more frequently. They are usually diagnosed in an
unexpected manner ("incidentalomas") by US or histopatho-
logical examinations of surgically excised glands in cases
with benign presentations, such as airway obstruction, large
goiter, and uncontrolled hyperthyroidism (8,9).
Epidemiological studies conducted in iodine-sufficient
regions demonstrate a 5 to 10% prevalence of palpable
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thyroid nodules in women and a 1 to 2% prevalence in men
(1,2,8-10). US studies have revealed the existence of thyroid
nodules in 19 to 67% of normal-risk female and elderly
individuals (3,10-14). These findings have been corrobo-
rated by autopsy studies (15). The increased nodularity and
diameter of the thyroid seems to be inversely proportional
to thyroid-stimulating hormone (TSH) levels (16-18). An
evolution to hyperthyroidism due to the development of
functioning autonomous nodules occurs in approximately
10% of cases over a ten-year period (19-21).
FNAB-US assessment is currently recommended for
nodules with a diameter larger than 1 cm and for nodules
smaller than 1 cm with suspicious features (hypoechogeni-
city, microcalcifications, border irregularity, and Doppler
central flow) (8,9,13,22,23) detected by ultrasound. An
ultrasound examination is indicated in all cases of suspected
nodules, and an initial TSH serum assessment should be
performed in addition to scintigraphy when a functional
nodule is confirmed (9).
The majority of patients with thyroid nodules can be
treated conservatively because 90 to 95% of nodules are non-
functional, benign nodules with associated mortality rates of
less than 1% (1,8,9,13). In particular, female gender, age
between 20 and 45 years, nodules smaller than 2 cm, lack of
multicentricity on US, absence of a glandular capsule, and
locoregional lymph node outbreaks are considered to be
factors related to low malignancy risk (8,9,13,16). Thus, it is
important to properly select candidates for surgery based on
the suspicion of malignancy (16,21,22).
Various clinical, ultrasound, and cytological parameters,
such as age, gender, nodularity, TSH level, thyroid auto-
immunity, and ultrasound findings (hypoechogenicity,
microcalcifications, irregular borders, and increased central
nodular flow), have been studied to improve diagnostic
accuracy and differentiate between benign and malignant
nodules (9,13-16,22). The literature indicates higher malig-
nancy rates in individuals below 16 or above 45 years of age
(8,13). There is no male or female predominance, even though
the incidence of nodules is higher in women (8,9). Some
studies have found a higher malignancy rate in patients with a
solitary nodule than in patients with multiple lesions (21),
although more recent reports have not confirmed this
association (8,22). Therefore, the results are conflicting, and
the samples studied are often not representative, due to either
short follow-up times or low correlations between the factors
studied (1,2,8,10,13-16).
Cytopathologically characterizing and differentiating
between benign and malignant follicular lesions is practically
impossible (24). The identification of genetic or immunohis-
tochemical markers that can distinguish both follicular
adenoma from follicular carcinoma and papillary hyperpla-
sia from papillary carcinoma remains a long-standing goal.
However, these markers remain inadequate for use in clinical
practice (24-27).
This review aims to discuss current thyroid nodule
management, diagnosis, and malignancy prediction using
ultrasound imaging and clinical and cytopathological data.
The following terms were used in a Medline/Pubmed
search: thyroid nodule, management of thyroid nodules,
thyroid ultrasound, thyroid cytology, and FNAB of thyroid
nodules. Approximately 220 articles published in the period
from 2000 to June 2011 were analyzed. The consensual
results pertinent to the topic were described to both examine
the major diagnostic concerns and to explore more accurate
therapeutic approaches for patients with thyroid nodules.
TSH LEVELS AND AUTOIMMUNE DISEASE IN
THYROID NODULES
Previous studies have shown that increased serum TSH
levels may be associated with an increased risk of thyroid
cancer in patients with nodular goiter (28-37). The risk of
thyroid malignancy increases with higher TSH concentra-
tions, even those within the normal range (28-30). Boelaert
et al. (30) studied 1500 consecutive patients without thyroid
dysfunction and found a higher risk of malignancy (an
adjusted odds ratio (AOR) of 2.72) in subjects whose TSH
levels ranged from 1.0 to 1.7 mU/L than in those with TSH
levels ,0.4 mU/L (an AOR of 1.00), with a particularly high
incidence found in those with TSH levels .1.8 mU/L (AOR
3.88). Males, younger patients, and patients with solitary
nodules were also found to have a higher risk of malignancy
(30).
Fiore et al. (37) studied the relationship between TSH
serum levels and papillary thyroid carcinoma (PTC) in
patients with uni- or multi-nodular goiter who were or were
not treated with levothyroxine. The treated patients had
lower TSH serum levels and decreased PTC prevalence. The
PTC prevalence was lower in the patients with TSH levels
,0.4 mU/ml and was greater in those with TSH levels
.3.4 mU/ml (1.9% vs. 16.5%), with no influence of age or
multiple nodularity.
In contrast, Gerschpacher et al. (35) compared the TSH
concentrations of 33 patients with papillary microcarcinoma
who underwent total thyroidectomy with those of a control
group with carcinomas larger than 1 cm (n = 54), and no
significant TSH concentration differences were observed
(1.40¡0.92 mU/L vs. 1.43¡1.44 mU/L). Moreover, these
results were not observed in the patients with indeterminate
nodules based on cytology (29,31-36).
Retrospective studies have reported a correlation between
thyroid malignancy and autoimmune thyroid disease (ATD)
(33-39), as well as a higher rate of malignancy in
Hashimoto’s thyroiditis (HT) nodules (22). In contrast,
Anil et al. (38) observed a 1.0% malignancy rate in patients
with HT vs. a 2.7% rate in a control group, a difference that
was not statistically significant. Mukasa et al. (40) observed
a higher malignancy rate in HT patients with nodules larger
than 1 cm or with smaller nodules exhibiting suspicious US
findings than in patients with Graves’ disease (1.77% vs.
0.97%). Adenomatous lesions were also more frequent in the
HT group and in patients younger than 40 years of age.
Thus, the most recent reports recommend measuring anti-
TPO and anti-thyroglobulin (anti-Tg) antibodies during
initial thyroid nodule investigations in which an elevated
TSH level (over the normal range) is found (8,9,22).
SCINTIGRAPHY AND THYROID NODULES
Scintigraphy and thyroid uptake have been utilized for
over 60 years. They are valuable procedures for investigat-
ing a number of thyroid dysfunctions, such as destructive
thyroiditis, ectopic thyroid, and hyperfunctioning nodules.
However, they have limited diagnostic value for iso- or
hypo-functioning thyroid nodules (8-10,41,42). Scintigraphy
(and thyroid uptake with radioactive iodine or perthecne-
tathe-Tc99m when TSH is subnormal) is recommended for
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evaluating functional nodules (9,22). Hyperfunctioning
nodules are almost always benign, while non-functioning
nodules carry estimated malignancy risk rates of 10 to 20%
(8,9,22). Additionally, scintigraphy is indicated for deter-
mining the functional status of nodules with indeterminate
cytology; the goal is to detect hot nodules that are probable
follicular adenomas and to differentiate between the
nodules in multinodular goiters (43).
Due to improved nuclear imaging methods, studies using
dynamic nuclear magnetic resonance (NMR) imaging have
become increasingly frequent. Gupta et al. (44) recently
studied the impact of NMR spectroscopy techniques on the
detection of thyroid follicular neoplasms. Choline peaks
were observed in eight of the analyzed cases of follicular
carcinoma, with a sensitivity of 100% and a specificity of
94%. Due to the limited follow-up duration and small
sample size, the method still needs validation in larger
studies. In contrast, Kim et al. (45) did not find FDG-PET
to be satisfactory for defining malignancy in the thyroid
nodules of 50 patients; therefore, it is still considered to be a
low-efficacy method.
ULTRASOUND OF THYROID NODULES
Cervical ultrasound is the method of choice for studying
thyroid nodules, and it enables the evaluation of the size,
location, and characteristics suggestive of malignancies
(Figure 1) (8,9,14,22,46-48).
According to Leenhardt et al. (49), hypoechogenicity has a
moderate positive predictive value (50 to 63%) for malig-
nancy in thyroid nodules, with high sensitivity (75%) and
specificity (61 to 83%) for US examination. Li et al. (50)
reviewed the US features of 115 nodules in 104 patients with
PTC and found that microcalcifications, central flow, and
irregular borders were directly associated with malignant
thyroid nodules. Gonzalez-Gonzales (51) studied the US
characteristics of 341 thyroid nodules and found that
microcalcifications were the only variable that was signifi-
cantly associated with malignancy.
Moon et al. (32) analyzed 1083 thyroid nodules and found
that central flow is the most common distinction between
benign and malignant nodules. Of the 1083 nodules studied,
814 were benign and 269 were malignant. Intranodular
vascularity was frequently observed in the benign nodules,
and vascularity was more typically absent in the malignant
nodules. These findings corroborate the results of Cantisani
et al. (34), who used Doppler to analyze vascularity in US
readings from 1090 patients and concluded that flow pattern
should not be used as the sole predictor of malignancy
or other thyroid nodule characteristics; therefore, FNAB
remains mandatory.
Baier et al. (52) evaluated the US data and the clinical and
laboratory characteristics of 944 patients with thyroid
nodules and noted an association between malignant solid
nodules and patient age younger than 45 years. In contrast,
Choi et al. (53) found no association between age and
malignancy in nodules with indeterminate cytology. The
authors studied the cases of 165 patients who had been
diagnosed with "follicular tumors’’ and found no significant
associations between malignancy and gender, age ($45
years), diameter, or US characteristics, although there was a
significant association with central flow by Doppler study.
According to the literature, the malignancy rate in thyroid
nodules that are 4 cm or larger, with indeterminate
cytology, varies from 10 to 30% (22,40,42,49,50). Rosa´rio
et al. (45) found malignancies in 23.5% of the cases with
indeterminate cytology. They found suspicious character-
istics in the ultrasounds of 76% of these nodules, compared
with 6.5% of the nodules with no suspicious aspects. In a
recent analysis, Kihara et al. (54) found no association
between nodule size or thyroglobulin level and malignancy
risk in 137 surgically treated patients. However, they
observed that malignancy was directly associated with
suspicious US findings. These findings were similar to those
of Maia et al. (56), who assessed the correlations among the
cytological variables of the Bethesda system and the clinical,
ultrasound, and scintigraphic data from patients with
thyroid nodules with indeterminate cytology. Malignancy
was found in 68.4% of the nodules with suspicious US
characteristics vs. 14.8% of those with normal US findings.
After the multivariate analysis, border irregularity as
observed by US and Bethesda IV category were able to
accurately predict malignancy in 76.9% of the thyroid
nodules with indeterminate cytology.
Figure 1 - Ultrasound parameters suggestive of malignancy in thyroid nodules. Adapted from Lew et al. (14).
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Stojadinovic et al. (55) studied 216 patients with thyroid
nodules who were examined by US and electrical impe-
dance (EIS) scanning prior to FNAB and thyroidectomy. A
Bayesian network model successfully predicted malignancy
based on the EIS technique. The model’s positive and
negative predictive values were 83 and 79%, respectively.
These studies require the use of this technique on a large
scale with elaborate protocols and long-term follow-up to
confirm their effectiveness and practicality.
Combinations of ultrasound characteristics and clinical,
laboratory, and cytological markers have frequently been
examined in studies that aim to establish prediction models
for thyroid malignancies (43,46,47,52-55,57-59).
According to the UICC/AJCC, a classification system
based on the pTNM parameters and age at diagnosis should
be used to categorize the severity of all types of tumors,
including thyroid cancer (60,61). Age is one of the criteria in
this system, which uses 45 years of age as the cutoff point.
This cut-off point was corroborated by Banks et al. (36) and
Baier et al. (52).
Although the rate of thyroid nodules is 5 to 11 times higher
in females, the annual incidence of thyroid cancer in the
United States is approximately 1.2 to 2.6 per 100,000 males
and 2.0 to 3.8 per 100,000 females (7,8,10,52,62,64). While some
authors believe that males have a 2- to 3-fold greater risk of
thyroid nodule malignancy, caution should be exercised in
the interpretation of this result (60,65) because other studies
have not demonstrated such a difference (56,66,67). Several
studies have shown the importance of age and male gender as
prognostic markers for thyroid cancer, regardless of the
ultrasound characteristics (9,62,63,68,69).
Alves et al. (70) studied clinical, scintigraphic, ultrasound,
and cytological predictors and observed that aspiration
cytology yielded better results (sensitivity of 94% and
specificity of 97%) than scintigraphy (sensitivity of 89%
and specificity of 21%) or US (sensitivities ranging from 60
to 100% and specificities ranging from 25 to 69%).
Another study has proposed a risk analysis based on
patient age (older than 50 years), nodule size (2.5 cm), and
cytological criteria (nuclear atypia and indefinite or suspi-
cious cytological results) (36). For nodules with diameters
less than 2.5 cm, the risk of malignancy was increased by
53% for each 1-cm decrease beginning at 2.5 cm. For larger
nodules, the risk increased by 39% for each 1-cm increase.
The patients with cytology results suspicious for papillary
thyroid carcinoma had the greatest risk of malignancy.
Maia et al. (71) evaluated the risk factors for malignancy
in 143 patients with thyroid nodules. The FNAB sensitivity
and specificity for malignancy were 82.8 and 97.7%, re-
spectively. The age at diagnosis was an independent risk
factor for malignancy, with a cutoff point of 38.5 years. The
multivariate model showed that age .39 years, nodule size
$2 cm, microcalcifications, and border irregularity based on
ultrasound study were predictive factors for malignancy,
with a combined accuracy of 81.7%.
FINE-NEEDLE ASPIRATION CYTOLOGY
FNAB still remains the most important method for
detecting malignancy in the management and monitoring
of thyroid nodules. It has a high sensitivity (65 to 98%) and
specificity (72 to 100%) (8,54,56,72), and it has a false-
positive rate for cancer detection of 0 to 7% and a false-
negative rate of 1 to 11% (8,54).
Physician experience is quite important for performing
this procedure, and US-guided FNAB is preferable.
Similarly, pathologist experience in interpreting the aspi-
rated material can guide the therapeutic approach. The
procedure is relatively simple, quick, safe, low-cost, and
devoid of significant complications (8,9,22,40).
Choi et al. (73) found that 16.1% of 3.767 FNAB-US
samples were inadequate, largely due to the lack of
physician experience, a predominance of cystic lesions,
and the presence of macrocalcifications. Additionally,
Akgu¨l et al. (74) found no relationship between malignancy
and nodule diameter or clinical (age, gender, and functional
gland status) and ultrasound aspects in cases with inade-
quate cytology results. The authors found a 12.6% rate of
malignancy in nodules with unsatisfactory cytological
results.
Regarding the cytological variables, an indeterminate or
"follicular tumor’’ diagnosis was a significant problem when
attempting to identify malignancies. The authors (9) defined
four possible cytopathological results: benign, malignant,
suspicious for malignancy (follicular neoplasm or Hu¨rthle
cell carcinoma), or non-diagnostic. Thus, they estimated that
samples with indeterminate results ("follicular tumor")
represented approximately 15 to 30% (8,9,22) of their cases.
Given that 70 to 80% of the "undetermined" lesions were
eventually classified as benign in the final histological
analysis (8,16,22,23,43,46,47), surgery recommendations in
these case are problematic (8,23,27,43,46,47).
The Bethesda classification system was created to guide
cytopathological diagnoses and to help identify important
correlations with malignancy in the final histological study.
It consists of a six-category classification system associated
with increased risk of malignancy and is based on a
cytohistological analysis of 3207 FNAB samples from 2468
patients (Figure 2) (75). This classification system ensures
the uniformity of information shared among pathologists,
clinicians, and surgeons, and it provides better correlations
between malignancy and cytological results, thus enabling
more appropriate management.
Given these objectives, several studies have been con-
ducted regarding the cytological parameters that determine
malignancy. According to Kelman et al. and Goldstein et al.,
the presence of cellular atypia in indeterminate cytology
nodules indicates a greater likelihood of malignancy (76-78).
Lubitz et al. (79) determined that nine of the 17 cytological
characteristics examined in a study of 144 patients were
associated with malignancy. In their multivariate analysis,
only the presence of vascular transgressions and nuclear
cracks were correlated with malignancy in the nodules
investigated.
Yehuda et al. (80) studied the predictive value of certain
cytological variables, including "atypia", when predicting
thyroid nodule malignancies in 111 patients and found a
56% malignancy rate in the final histological analysis.
Micro-nucleoli, irregular nuclear contours, and dense
chromatin were the most frequent characteristics noted in
the malignant tumors, and there was an 83% probability of
malignancy when these three characteristics were present.
However, cellular atypia was present in 66% of the
malignant nodules and in 78% of the benign cases, a
difference that was not significant.
Kato et al. (81) studied the specificity of 4 cytological
variables indicative of "atypia" for predicting malignancy in
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466 surgically treated patients with cytologically indetermi-
nate thyroid nodules. The "atypia" FNAB diagnosis was
associated with a 42% risk of malignancy. This risk was 7%
when there were no atypical features and 81% when there
were four or more. When irregularity and nuclear inclusions
were present, there was a 79.3% probability of malignancy
and 98% specificity, which is similar to the findings of
Yehuda (65). In summary, several cytological, clinical, and
laboratory parameters have been studied as predictors of
malignancy in thyroid nodules, especially in nodules with
indeterminate cytology (Figure 3).
Maia et al. (82) evaluated the correlation between the
cytological variables of the Bethesda system and clinical,
sonographic, and scintigraphic data on indeterminate thy-
roid nodules. In a sample of nodules with a 25% malignancy
rate, category IV of the Bethesda system was an independent
predictor of malignancy. A blind review of the cytology
results by a specialized cytopathologist with experience in
thyroid studies resulted in a 10.9% reduction in the cases
classified as Bethesda category III or IV, most of which were
reclassified as benign cytology (category II); these results
were confirmed by the post-surgical treatment. Davidov et al.
(83) evaluated the Bethesda classification data of 250 patients
who had their FNAB results reviewed by a second
pathologist. There was diagnostic agreement between the
first analysis and the second opinion in 66% of the cases. The
highest concordance rate occurred in the malignant cytology
group (categories V and VI), while the rate was only 37% in
the indeterminate cytology group (categories III and IV). The
second opinion increased the FNAB diagnostic accuracy by
14% and reduced the surgery rate by 25%. Such results
demonstrate the importance of cytological review by a
pathologist experienced in thyroid surgery recommendations
for patients with indeterminate cytology (82,83).
Figure 2 - The Bethesda cytological classification system and its correlation with the risk of thyroid nodule malignancy. Adapted from
Theoharis et al. (60).
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TUMOR MARKERS OF THYROID CYTOLOGY (FNAB):
INDICATIONS AND CLINICAL APPLICATIONS
This discussion refers to the accuracy and specificity of
methods and molecular markers of thyroid malignancy, as
well as to the appropriate timing of the immunocytochem-
ical analysis of FNAB samples. The appropriate indication
of molecular immunocytochemical markers of malignancy
increased with the diagnostic pitfalls of Bethesda categories
III, IV, and V (20,24,25,84,85).
Galectin 3 (Gal-3) immunodetection is one of the most
widely studied markers for malignancy in follicular lesions
with indeterminate cytology (20,24,25). Bartolazzi et al. (46)
examined Gal-3 expression in 1009 thyroid lesion samples
and 226 FNAB cytological results, which showed 98%
sensitivity and 99% specificity to discriminate benign and
malignant lesions. Pennelli et al. (85) corroborated these
results by observing an 80% sensitivity and an 86% specificity
in a group of one hundred indeterminate cytological nodules.
The BRAF (V600E) mutation, which is characteristic of PTC,
has provided greater diagnostic accuracy for nodules with
indeterminate cytology and for nodules that are suspicious for
malignancy (20,23,26). While researching the BRAF (V600E)
mutation, Kim et al. (47) studied 1074 patients with thyroid
nodules and observed an increase in the FNAB sensitivity
from 67.5 to 89.6% and an increase in the accuracy from 90.9 to
96.6%. In another analysis, Nikiforov et al. (27) reviewed 470
cytology specimens from 328 patients for BRAF mutations,
RAS mutations, RET/PTC markers, and PAX8/PPAR gamma
mutations. BRAF mutations were the most common finding,
and the presence of three mutations was predictive of a
malignancy diagnosis in 97% of the confirmed cases.
Cerruti et al. (86) analyzed four protein markers from
cytology material (FNAB) to evaluate thyroid nodules with
suspected malignancy. Greater diagnostic accuracy was
observed when both proteins derived from chromosome 1
(chromosome 1 open reading frame 24, C1orf24) and membrane
protein 1 (integral membrane protein 1, ITM1) were present.
Additionally, the BRAF mutation (V600E) was verified in
48% of the 120 papillary carcinoma cases evaluated and
occured more frequently in the classic PTC cases (66%) than
in the follicular PTC variant (21%). Furthermore, there was a
strong association between the BRAF (V600E) mutation and
extra-thyroid invasion, lymph node metastasis, and recur-
rence risk, indicating that the mutation is an important
prognostic marker for classic PTC.
According to Fadda et al. (87), it is possible to identify two
risk categories (high and low) in nodules with indeterminate
cytology (follicular neoplasms) based on HBME-1 and Gal-3
expression. Indeterminate cytology was present in 50 of 120
surgically treated cases. In these 50 indeterminate tumors, a
positive immunohistochemical panel was observed in 76.9%
of the cases with malignant nodules in the final histology,
and a negative panel (no positive markers) was observed in
almost all (96.8%) of the benign cases. These data were
corroborated by Kang et al. (88) in an analysis of the
BRAFV600E mutation in (preoperative) FNAB samples from
200 surgically treated thyroid nodules. The mutation was
present in 63.3% of the malignant cases with initially
indeterminate cytology. Therefore, for nodules with inde-
terminate cytology (Bethesda categories III and IV), negative
tumor markers (HBME-1 and Gal-3) in the FNAB sample
suggests conservative management, and a positive immu-
nohistochemical panel suggests surgical treatment.
FOLLOW-UP OF THYROID NODULES WITH
INITIALLY BENIGN CYTOLOGICAL RESULTS
Thyroid nodules with a benign diagnosis in the initial
cytological evaluation have long been thought to require
only cervical sonographic assessment for long-term follow
up, regardless of the results of the US examination. Despite
a false-negative rate that has been classically established at
5% (8,9), several authors have demonstrated the value of
repeat FNAB studies for certain thyroid nodules with
initially benign cytology (43,60,89-93). There is still con-
troversy over what criteria should be used to select such
nodules and over whether systematically repeating FNAB
Figure 3 - Malignancy parameters in nodules with indeterminate cytology. Adapted from Banks et al. (50) and Yehuda et al. (65).
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studies to minimize the number of false-negative results is
justified. In solid-nodule cases (including mixed nodules
with solid portions) where the growth is less than 20%
of the diameter in two dimensions, the appropriate US
follow-up interval may be as long as every 3 to 5 years
(8,22,30,47).
Thus, some aspects of managing nodules with initially
benign cytology deserve further discussion. According to
some authors, the risk of malignancy is lower for initially
benign thyroid nodules without suspicious US character-
istics (0.6%) than in those with US results that suggest
malignancy (20.4%) (94). Of 122 surgically treated thyroid
nodules, 23 (18.8%) of those with initially benign cytology
were found to be malignant after being reaccessed by FNAB
at an average interval of 15.5 months. The authors
concluded that repeated FNAB studies of initially benign
nodules with suspicious US results increases malignancy
detection during follow-up.
Kwak et al. (89) reviewed sonographic-cytological corre-
lations in 568 patients to determine whether repeated FNAB
studies are indicated for thyroid nodule follow-up. The
authors found a high risk of malignancy (92 to 98%) in
thyroid nodules that were classified as "malignant" or
"suspected for malignancy’’, regardless of the US findings.
For nodules with initially benign cytology, however,
suspicious US findings correctly predicted malignancy in
more than half of the cases (56.6% vs. 2.9%). Repeated FNAB
studies revealed "suspected" or "malignant" cytology in 15
(93.8%) of the 16 thyroid carcinomas that were detected
during the follow-up. The authors recommended repeated
FNAB studies for nodules with initially benign cytology and
suspicious US findings.
Studies on the management of supposedly benign ("Thy
2") thyroid nodules using the "Thy 1-5" cytological
classification system suggest performing an additional
FNAB after 3 to 6 months for diagnostic confirmation and
to reduce the false-negative rate, regardless of the clinical or
ultrasound findings (13,23).
Illouz et al. (95) analyzed 119 surgically treated thyroid
nodules and found that systematically repeating FNAB
studies detected 22.7% of the malignant nodules that were
undiagnosed in the initial cytology. The authors recom-
mend at least three FNAB studies to reduce the false-
negative rate and accurately diagnose malignancy. A retro-
spective analysis of more than ten thousand FNAB studies
demonstrated that the procedure increased the diagnostic
accuracy by 8% (from 90 to 98%) when it was sequentially
performed (96). The use of repeated biopsies for initially
benign nodules reduced the FN misdiagnosis rate from 5.2%
to less than 1.3%.
Orlandi et al. (92) studied 799 sequential, annual FNAB-
US studies with favorable results. The studies were
performed on 302 patients over 2 to 12 years of follow-up.
The authors concluded that FNAB monitoring could be
discontinued after at least three benign cytology assess-
ments when clinical suspicion was absent.
Flanagan et al. (90) observed that repeating FNAB up to
three times increased the sensitivity from 81.7 to 90.4% and
reduced the FN rate by 6.7%. Sensitivity did not increase
between the third and the fifth procedures in this study,
suggesting that up to three systematic FNAB studies are
sufficient for making clinical or surgical decisions about
suspected malignancies. Similarly, Maia et al. (97) found a
malignancy prevalence of 28.5% in nodules with initially
benign cytology that underwent repeated FNAB studies,
which raised the malignancy diagnosis rate by 7%. Of these
cases, 82.1% were identified by the third FNAB-US (there was
a 13-month interval between the first and third procedures).
The ultrasound analysis demonstrated that features sugges-
tive of malignancy (microcalcifications, border irregularities,
central flow, and hypoechogenicity features) were signifi-
cantly more common in the malignant nodules group. Kwak
et al. (94) found that 25% of nodules with initially benign
cytology exhibited significant growth when examined in
repeated FNAB studies. However, this group demonstrated
an average malignancy rate of 1% compared with a rate
of 20% obtained by ultrasound detection of malignant
parameters.
Other authors have contested this position and recom-
mended against repeated FNAB studies due to their high
specificity and to the low cost-effectiveness of repeating the
procedure in large numbers of nodules that have been
diagnosed as benign (98-100). Aguilar et al. (101) found no
changes from the initial diagnosis in 99.5% of the 184
nodules they investigated, and only one (0.5%) was later
diagnosed with a malignancy. Similarly, Mittendorf and
McHenry (102) found that initially benign cytology findings
remained unchanged in 86.7% of the cases with follicular
lesions; malignancies were found in 6.7%.
This discussion is important because it is part of the
routine clinical monitoring of patients with suspicious US
features and benign FNAB cytological results. Clinical US
follow-up should be performed every 12 to 18 months
(9,22,23); nonetheless, patients with initially benign cytolo-
gical results and suspicious US findings have been found
to have higher malignancy rates during repeated FNAB
follow-up than patients without suspicions US findings (97).
A consensus review by the American Association of Clinical
Endocrinologists (AECA), the ATA and the European
Thyroid Association revealed that 31% of the 166 specialists
interviewed would order another FNAB 6 to 12 months
after obtaining initially benign cytological results, regardless
of the recommended guidelines (103), and that only 6%
would request an immunohistochemical panel after inde-
terminate cytology. This indication has become increasingly
consistent in HBME-1, Gal-3, and BRAFV600E immunohis-
tochemistry studies (87,88).
The current clinical accuracy of these clinical and
laboratorial variables (ultrasound or scintigraphy, cytology,
and possible repeated FNAB studies) as malignancy
predictors for thyroid nodules is still controversial.
FINAL CONSIDERATIONS
The literature from the last five years has revealed new
prospects for and trends in the approach to the diagnosis
of thyroid nodules, with greater emphasis on US review
and investigations of cytological tumor markers. An
US review combined with cytological data (including the
Bethesda classification system) improves the accuracy and
efficiency of thyroid nodule malignancy prediction in cases
with indeterminate cytology, especially when reviewed by
thyroid pathology experts. In most of the published
studies, the use of ultrasound criteria to determine
whether to perform repeated FNAB-US studies for nodules
with initially benign cytology increased the diagnostic
accuracy for malignancy over a mean follow-up of 12-18
months. Higher malignancy rates have been observed in
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initially benign nodules with suspicious US findings than
in those evaluated using the widely used nodule growth
criteria.
The use of US malignancy criteria combined with Bethesda
categories III or IV improves malignancy detection, and they
should be considered to guide surgical decisions for this
group of nodules.
Determination of the clinical applicability of genetic and
molecular markers in FNAB samples requires additional,
consistent long-term studies. The initial results presented
in this field of FNAB immunohistochemical markers, were
satisfactory for making decisions about which patients
required surgery or clinical-follow up in specific cases,
especially those with indeterminate cytology. The BRAF
V600E mutation and the simultaneous cytological expres-
sion of HBME-1, Gal-3, and CK-19 improve malignancy
prediction and are good candidates for guiding surgical
decisions for Bethesda category III and IV nodules.
Malignancy prediction models are increasingly desirable
for establishing early diagnoses and improving surgical
decisions in specific patients, such as those with indeter-
minate or undiagnosed cytology thyroid nodules.
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